Vol.

No.

January 27, 2023Jan 27, 2023

DOWNLOAD THE PDF

Cover Story

Epigeneticists may be looking for epigenome-disease associations in the wrong place

By Jacquelyn Cobb and Matthew Bin Han Ong

For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.

Conversation with The Cancer Letter

Baylor’s Waterland & Coarfa: We see CoRSIVs as the new standard in epigenetic epidemiology

By Jacquelyn Cobb and Matthew Bin Han Ong

Guest Editorial

NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

By Lisa M. Coussens

Clinical Free Trials & Tribulations

Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”

By Mark J. Ratain and Garth W. Strohbehn

Cancer History Project Conversation with The Cancer Letter

Jim Allison believed in the power of T cells—when hardly anyone else did

By Alexandria Carolan

Free In the Archives

Duke marks 50 years of gynecologic care; celebrates legacies of oncology doctors and nurses

In Brief

Jeffrey Holzbeierlein named physician-in-chief at KU

Richard D. Carvajal named deputy physician-in-chief and director of medical oncology at Northwell Health Cancer Institute

Travis Poole named associate director of research administration at MUSC Hollings

UPMC Hillman receives $11M SPORE in head and neck cancer

Jason Luke named interim associate director for clinical research at UPMC

Sylvester, Emory researchers receive $3.3M NIH grant to study sMRI

Pedro Torres-Ayuso receives $50,000 to study gene as target in squamous cell head and neck cancers

Grassley, Durbin, Tillis, Coons introduce legislation to strengthen coordination between Patent Office, FDA

Clinical Roundup

Rutgers investigators explore impact of cigarette smoking and alcohol consumption on Black breast cancer survivors

IARC, GICR study reports marked differences in cancer survival internationally

Clinical study evaluating Breyanzi met primary endpoint in R/R CLL

Medical College of Wisconsin scientists find marker that may predict immunotherapy response in ER+ breast cancer

UCLA researchers identify possible approach to prevent cancer from evolving to resist treatment

Sylvester study addresses one of the major mechanisms of pancreatic cancer treatment resistance

Hopkins study points to cause of pancreatic cancer immunotherapy resistance

“Persistent mutations” in tumors may predict response to immunotherapy

OSUCCC—James study suggests inhibition of SUSD2 protein improves CAR T-cell therapy effectiveness

OSUCCC—James study suggests a way to re-energize tired T cells when treating cancer, viral infections

Moffitt research suggests that sugar found in seaweed triggers potent antitumor immune responses and enhances immunotherapies

Drugs & Targets

FDA approves Keytruda as adjuvant treatment for NSCLC

FDA approves Brukinsa for CLL or SLL

AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

AstraZeneca, Ibex collaborate on AI-powered HER2 scoring product

Evotec, Janssen collaborate to develop immune-based therapies

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 05 - February 06, 2026